SOURCE: Enterey, Inc. Life Sciences Consulting

Enterey, Inc. Life Sciences Consulting

September 05, 2012 13:08 ET

Enterey Consulting Partners With DEI to Support the Creation and Protection of Shareholder Value for the Life Sciences

IRVINE, CA--(Marketwire - Sep 5, 2012) - Enterey Life Sciences Consulting, a leading provider of consulting services focused on manufacturing and quality operations for life sciences companies, introduces Decision Empowerment Institute (DEI) PRO-Enterprise Management Risk Quantification Approach for assessing operational and compliance risk, resulting in a sustainable risk-mitigation strategy and protecting potentially billions in shareholder value.

Can you, as a stakeholder in your organization, answer the following "Five Questions" related to your company's problems, risks, and opportunities (PRO)?

1. What are your PRO items?

  • Below-sales forecast for products/services (Problem)
  • Unreported adverse drug events and inconsistent NDA safety database (Risk)
  • Improve clinical trial supply forecasting (Opportunity)

2. Which erode the most value if not pursued?

3. Which, if pursued, create or protect the most value?

4. Which should you pursue?

5. What are the implications to your plan and budget?

Brian Hagen, managing director of Decision Empowerment Institute, states that to quantify risk using this approach also helps risk managers decide whether to act or not on any particular exposure. He says that, "Once you have the numbers, you can decide how to adjust your mitigation."

In a recent pilot program, a process manufacturing company was ready to cease making one of its products because the supply chain costs were too high. "We used [the DEI approach] as a test case," a company official said, "and after running the calculations for two or three weeks, the data came back that we should continue to manufacture [this product]. We were even able to get hard data on the most economical supply-chain alternatives."

On another client project, the primary risk-management goals identified were to:

1) Avoid product interruption
2) Understand revenue impact when product production interruption occurs
3) Develop a method for predicting and managing future risk

For this client, expectations included:

1) Being able to run the top risks through a standard model
2) Modeling how they can analyze world events and the resultant broad impact (e.g., tsunami impact)
3) High-level business decision-making to analyze risk
4) Creating a risk analysis center of excellence (COE) organization to define an operational structure
5) Working with operations strategic planning (OSP)

According to Enterey CEO Mike Ferletic, "Establishing tools to analyze spend and resource utilization will not only save significant investment, but will also provide a means to proactively evaluate future changes to production when demand changes," and, he says, "these tools give insight as to how to handle those changes." The result of DEI's approach for quantifying operational and compliance risk and decision-making has resulted in millions of savings to shareholders' bottom lines.

Enterey Life Sciences Consulting, founded in 2002, provides life sciences consulting expertise in both process- and systems-related projects for biotech, medical device, and pharmaceutical clients. Enterey provides solutions ranging from strategic planning to business-integration, and has a proven track record of success supporting both clinical and commercial facility start-ups.

For information about Enterey, visit: or call (800) 691-2349.

Contact Information

  • Media contact:
    Tita Tavares
    Enterey, Inc.
    949.336.5200 x 106
    Email Contact